Multiple Myeloma Clinical Trial
Official title:
Multiple Myeloma in the French West Indies. Environmental and Professional Exposure to Pesticide: A Case-control Study in Guadeloupe and Martinique
Multiple myeloma (MM) is a malignancy of plasma cells engaging in monoclonal immunoglobulin production. A strong presumption was established between exposure to pesticides and the risk of MM. The French West Indies departments of Guadeloupe and Martinique are characterized by a wide use of pesticides related to bananas plantation, particularly chlordecone which has been classified by IARC as possibly carcinogenic and has recognized hormonal properties (endocrine disruptor). The objective of this study is to measure the association between exposure to pesticide and other environmental factors in the occurrence of MM in Guadeloupe and Martinique and to estimate the proportion of cases of MM attributable to pesticide exposure. Genetic susceptibility markers and their links to environmental factors will be subsequently studies from blood samples collection.
Multiple Myeloma (MM) is a mature B-cell lymphoma characterized by monoclonal proliferation
of tumor plasma cells invading the bone marrow. It is the second malignant hemopathy among
Non-Hodgkin's Lymphomas. Etiology of the disease is poorly understood. Its higher incidence
in black subjects suggests the existence of genetic factors. Numerous studies have evoked the
role of exposure to environmental and occupational factors in the occurrence of MM such as
exposure to pesticides, solvents, in particular benzene, and other petroleum derivatives, as
well as work in an agricultural environment, in hairdressing and in the metallurgical and
textile industries. According to the Collective Inserm expertise "Pesticides and Health", a
strong presumption (++) has been established between exposure to pesticides and the risk of
occurrence of MM.
In the French West Indies (Guadeloupe, Martinique), the incidence of MM is higher than in
France. These 2 departments are characterized by a major use of pesticides in connection with
the banana culture developed intensively from the 1950s. These cultures successively used
organochlorine insecticides, mainly β-hexachlorocyclohexane (β-HCH), technical HCH (mixture
of α, β, and γ isomers of HCH), and especially chlordecone (CLD). CLD was used from 1972 to
1993 under the trade names of Kepone® (1972-1978) and then Curlone® (1982-1993) with a CLD
rate of 5%. The absence of biotic and abiotic degradation of CLD has resulted in persistent
soil pollution, still present today, contamination of surface and deep waters, many plant and
animal products, terrestrial and marine, and then the population. CLD is a proven carcinogen
in rodents, classified as a possible carcinogen by the International Agency for Research on
Cancer (IARC) and has recognized hormonal properties (endocrine disruptor). CLD has been
associated with an increased risk of prostate cancer in Guadeloupe. In Martinique, a
geographic correlation study has shown a high incidence of MM in individuals residing on
soils polluted by CLD.
Studies on the impact of pesticides on health come up against numerous limits, in the
foreground of which is the great diversity of products (more than 900 active ingredients were
approved one day in France and marketed in more than 9000 different products) and the
difficulty in reconstructing retrospectively and objectively the exposures of individuals due
to the multiplicity of sources of exposure (leisure, gardening, domestic use).
Mode of action of pesticides is still insufficiently documented, but some are classified as
genotoxic, immunotoxic, tumor promoters or endocrine disruptors. Data available in the
literature mainly relate to case-control or cohort studies on the occupational exposure of
agricultural workers in industrialized countries. Measurement of this exposure is mainly made
from self-administered questionnaires.
The investigators propose to assess feasibility of a case-control study on role of exposure
to pesticides, in particular to CLD and persistent pollutants, as well as other occupational
exposures in the occurrence of MM in the West Indies. This study is part of the
recommendations of the Inserm-InVs Chlordecone Scientific Council and action 18 of the
National Interministerial Chlordecone Plan "initiate work on the link between myelomas and
exposure to chlordecone".
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05027594 -
Ph I Study in Adult Patients With Relapsed or Refractory Multiple Myeloma
|
Phase 1 | |
Completed |
NCT02412878 -
Once-weekly Versus Twice-weekly Carfilzomib in Combination With Dexamethasone in Adults With Relapsed and Refractory Multiple Myeloma
|
Phase 3 | |
Completed |
NCT01947140 -
Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies
|
Phase 1/Phase 2 | |
Recruiting |
NCT05971056 -
Providing Cancer Care Closer to Home for Patients With Multiple Myeloma
|
N/A | |
Recruiting |
NCT05243797 -
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
|
Phase 3 | |
Active, not recruiting |
NCT04555551 -
MCARH109 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of Multiple Myeloma
|
Phase 1 | |
Recruiting |
NCT05618041 -
The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies
|
N/A | |
Active, not recruiting |
NCT03844048 -
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
|
Phase 3 | |
Recruiting |
NCT03412877 -
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
|
Phase 2 | |
Completed |
NCT02916979 -
Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG
|
Phase 1 | |
Recruiting |
NCT03570983 -
A Trial Comparing Single Agent Melphalan to Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) as a Preparative Regimen for Patients With Multiple Myeloma Undergoing High Dose Therapy Followed by Autologous Stem Cell Reinfusion
|
Phase 2 | |
Terminated |
NCT03399448 -
NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells)
|
Phase 1 | |
Completed |
NCT03665155 -
First-in- Human Imaging of Multiple Myeloma Using 89Zr-DFO-daratumumab, a CD38-targeting Monoclonal Antibody
|
Phase 1/Phase 2 | |
Completed |
NCT02812706 -
Isatuximab Single Agent Study in Japanese Relapsed AND Refractory Multiple Myeloma Patients
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT05024045 -
Study of Oral LOXO-338 in Patients With Advanced Blood Cancers
|
Phase 1 | |
Active, not recruiting |
NCT03792763 -
Denosumab for High Risk SMM and SLiM CRAB Positive, Early Myeloma Patients
|
Phase 2 | |
Active, not recruiting |
NCT03989414 -
A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)
|
Phase 1/Phase 2 | |
Withdrawn |
NCT03608501 -
A Study of Ixazomib, Thalidomide and Dexamethasone in Newly Diagnosed and Treatment-naive Multiple Myeloma (MM) Participants Non-eligible for Autologous Stem-cell Transplantation
|
Phase 2 | |
Recruiting |
NCT04537442 -
Clinical Study to Evaluate the Safety and Efficacy of IM21 CAR-T Cells in the Treatment of Elderly Patients With Relapsed or Refractory Multiple Myeloma
|
Phase 1 | |
Completed |
NCT02546167 -
CART-BCMA Cells for Multiple Myeloma
|
Phase 1 |